Biohaven Pharmaceutical (BHVN) - Biznesning o‘zini qoplash muddati
Dori vositalarini ishlab chiqish va ishlab chiqarishda tashqi pudratchilarga kuchli bog'liqlik GURU.Markets grafigida Biohaven Ltd. kompaniyasining bazaviy P/E ko'rsatkichini belgilaydi, u yerda ushbu metrika -4.20 darajasida qolmoqda. Neyrodegenerativ patologiyalar terapiyalariga bo'lgan barqaror talab mijozlar sodiqligini ta'minlaydi. Biroq, operatsion foydaning yo'qligi va qimmat tadqiqotlar Biohaven Ltd. kompaniyasini doimiy ravishda zaxiralarni sarflashga va tashqi moliyalashtirishni izlashga majbur qilmoqda.
Biohaven Pharmaceutical (BHVN) kompaniyasining tahliliy kesimlari
- kotirovkalar va tahlilchilar prognozi:
- bozor kapitallashuvi ko'rsatkichlari:
- balans kapitallashuvi bo'yicha ma'lumotlar:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Umumiy qarzning kapitalga nisbati Biohaven Ltd.|BHVN - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati Biohaven Corp|BHVN - Kompaniyaning jamlangan qarzlari|Balans qiymatiga qarzlar Biohaven Ltd.|BHVN - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli qarzdorligi Biohaven|Oraliq qoplash koeffitsiyenti biohavenpharma.com
- biznes foydasi va investitsiya koeffitsiyentlari ma'lumotlari:
BHVN - Kompaniyaning sof foydasi|Kutilayotgan foyda Biohaven Ltd.|BHVN - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning kelajakdagi foydaga nisbati Biohaven Ltd|BHVN - PEG multiplikatori|Korxona qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati Biohaven Ltd.|BHVN - Eskirish chegirilmasdan oldingi operatsion foyda|So'nggi to'rtta chorak uchun bir aksiya uchun sof foyda Biohaven|BHVN - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi o'n ikki oy davomida bir aksiya uchun foydaning yillik o'sishi biohavenpharma.com|BHVN - Joriy yilda foyda o'sishi|Keyingi yilda bir aksiya uchun foydaning kutilayotgan dinamikasi Biohaven Ltd.
Kompaniyaning jamlanma tahlili:BHVN (biohavenpharma.com)
Barqaror aktivlarni qidirish foyda ko'rsatkichi (P/E) nisbatini tahlil qilishni talab etadi, bu esa kelajakdagi o'sish uchun premiumni va haddan tashqari to'lov qilish risklarini aniqlash imkonini beradi. Biohaven Ltd. (BHVN) holatida, kompaniyaning sof foydaga asoslangan P/E ko'rsatkichi FDA tasdig'iga oid spekulyativ kutishlarni aks ettiradi, chunki nevrologik dori vositalari sinovlarining joriy bosqichi ushbu metrikani kelajakdagi tijorat ishga tushirishga bo'lgan bozor ishonchining ko'rsatkichi qiladi.
Raqobatdosh kompaniyalar tahlili
Narxning foydaga nisbati BIIB|P/E multiplikatori NBIX|Biznesning o‘zini qoplash muddati Regencell Bioscience Ltd|Narxning foydaga nisbati Axsome Therapeutics Inc AXSM|ACADIA Corp (ACAD) - Kapitalizatsiyaning foydaga nisbati|Xenon Pharmaceuticals - P/E multiplikatori|Kompaniya qiymatining sof foydaga nisbati VKTX (vikingtherapeutics.com)|SUPN: P/E multiplikatori|Catalyst Pharma (CPRX) - P/E multiplikatori|Narx-foyda koeffitsiyenti DNLI|Narxning foydaga nisbati HRMY|P/E multiplikatori AMLX|TRVI - Kapitalizatsiyaning foydaga nisbati|Narxning foydaga nisbati Praxis Precision Medicines, Inc. PRAX|AVXL: Narx-foyda multiplikatori|CBLL: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati PRTA (Prothena Corporation)|alector.com (ALEC) - Narxning foydaga nisbati|ANNX (annexonbio.com) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti OMER|NGNE (Neurogene Inc) - Bozor narxining sof foydaga nisbati|P/E multiplikatori ACIU|Voyager Corp - Narx-foyda multiplikatori|Neumora Therapeutics - Narx-foyda koeffitsiyenti|Biznesning o‘zini qoplash muddati scilexholding.com (SCLX)|Tevogen Bio - P/E multiplikatori|ACOG: Narxning foydaga nisbati|CGTX: P/E multiplikatori|Inhibikase Pharma - Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti SAVA|Narxning foydaga nisbati ASRT|Narxning foydaga nisbati Coya Therapeutics, Inc. (COYA)|vistagen.com - Narx-foyda multiplikatori|Narxning foydaga nisbati Ovid Therapeutics OVID|ABOS: Narx-foyda multiplikatori|CervoMed Inc. - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Alterity Therapeutics|CLNN (clene.com) - Narx-foyda koeffitsiyenti|PepGen (PEPG) - P/E multiplikatori|Narxning foydaga nisbati Jupiter Neurosciences|RLMD: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Annovis Bio, Inc. (ANVS)|GRCE - Kapitalizatsiyaning foydaga nisbati|P/E multiplikatori AIFF (Firefly Neuroscience)|ANEW Medical - Narxning foydaga nisbati|NeuroSense Therapeutics, Ltd. - P/E multiplikatori|Biznesning o‘zini qoplash muddati Reviva Pharmaceuticals, Inc. RVPH|metaviatx.com (MTVA) - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati neuraxis.com (NRXS)|HSDT (Helius Medical Technologies, Inc.) - P/E multiplikatori|PASG: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori NEUP|P/E multiplikatori Minerva (NERV)|Athira Pharma, Inc. - Narx-foyda koeffitsiyenti|addextherapeutics.com - Narxning foydaga nisbati|Alzamend - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Cyclerion Therapeutics|protagenic.com (PTIX) - Narxning foydaga nisbati|Narx-foyda multiplikatori KTTA|Narx-foyda koeffitsiyenti CRGT|ATXI: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati BrainStorm Cell Therapeutics (BCLI)|Narxning foydaga nisbati CARA (Cara Therapeutics Inc.)|Chromocell Therapeutics Corporation - Narx-foyda koeffitsiyenti|Bozor narxining sof foydaga nisbati ELYM (Eliem Therapeutics, Inc.)|Intra-Cellular - P/E multiplikatori|LBPH (longboardpharma.com) - Narx-foyda multiplikatori|MRNS (Marinus Pharmaceuticals, Inc.) - Narx-foyda koeffitsiyenti|NKGN - Biznesning o‘zini qoplash muddati|NRBO (NeuroBo) - P/E multiplikatori|Narxning foydaga nisbati SAGE|P/E multiplikatori SNPX|TRVN (trevena.com) - Kompaniya qiymatining sof foydaga nisbati|Vigil Neuroscience, Inc. - Narx-foyda koeffitsiyenti|anewmeds.com - Narxning foydaga nisbati|CERE - Narxning foydaga nisbati
